Dipeptidyl peptidase-1 inhibitors in bronchiectasis
Emma Johnson1, Amy Gilmour1, James D Chalmers2
1Division of Respiratory Medicine and Gastroenterology, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Summary
Dipeptidyl peptidase (DPP)-1 inhibitors are the first disease-specific therapy for bronchiectasis. These inhibitors reduce neutrophil serine proteases, improving exacerbations and lung function.
Area of Science:
- Pulmonary Medicine
- Inflammation Research
- Pharmacology
Background:
- Bronchiectasis is characterized by chronic airway inflammation driven by neutrophil serine proteases (NSPs).
- High levels of NSPs in the airways correlate with increased disease severity in bronchiectasis.
- DPP-1 (cathepsin C) plays a crucial role in activating NSPs during neutrophil maturation.
Purpose of the Study:
- To evaluate the efficacy of Dipeptidyl peptidase (DPP)-1 inhibitors as a disease-specific therapy for bronchiectasis.
- To investigate the mechanism of action of DPP-1 inhibitors in suppressing NSP activity.
- To assess the clinical benefits of DPP-1 inhibition on exacerbations, quality of life, and lung function decline.
Main Methods:
- Review of Phase 2 and Phase 3 clinical trials investigating DPP-1 inhibitors in bronchiectasis patients.
- Analysis of data on NSP activity levels in airways before and after DPP-1 inhibitor treatment.
- Assessment of clinical endpoints including exacerbation rates, quality of life scores, and lung function parameters.
Main Results:
- DPP-1 inhibitors have demonstrated effectiveness in reducing NSP activity in the airways of bronchiectasis patients.
- Clinical trials confirmed significant reductions in exacerbations and improvements in quality of life.
- Slowing of lung function decline was observed in patients treated with DPP-1 inhibitors.
Conclusions:
- DPP-1 inhibitors represent a novel, disease-specific therapeutic strategy for bronchiectasis.
- The suppression of NSP activity by DPP-1 inhibitors leads to tangible clinical benefits.
- DPP-1 inhibition holds promise for other inflammatory conditions involving neutrophils.
More Related Videos
07:10Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
Published on: May 20, 2019
13.8K
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
1.1K
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:19Antiasthma Drugs: Leukotriene Modifiers
502
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
502
01:26COPD: Management Using Bronchodilators and Corticosteroids
329
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
329
01:17Drugs Used in Lower Respiratory Disorders: Overview
629
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
629
01:23Inhaled Medications
414
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
414
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260